BCD 600

Drug Profile

BCD 600

Alternative Names: BCD-600

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIOCND
  • Class Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Stomatitis

Highest Development Phases

  • Preclinical Stomatitis

Most Recent Events

  • 16 Dec 2016 BCD 600 is available for licensing as of 16 Dec 2016. http://www.biocnd.com/eng/research/research_010100.html
  • 16 Dec 2016 Preclinical trials in Stomatitis in South Korea (unspecified route)
  • 16 Dec 2016 BIOCND plans a phase I trial for Stomatitis in USA (BIOCND pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top